These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 8668278)

  • 1. [Variation in the diagnosis and treatment of benign prostatic hyperplasia in urological practice].
    Stoevelaar HJ; van de Beek C; Casparie AF; Nijs HG; McDonnell J; Janknegt RA
    Ned Tijdschr Geneeskd; 1996 Apr; 140(15):837-42. PubMed ID: 8668278
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment choice for benign prostatic hyperplasia: a matter of urologist preference?
    Stoevelaar HJ; Van de Beek C; Casparie AF; McDonnell J; Nijs HG
    J Urol; 1999 Jan; 161(1):133-8. PubMed ID: 10037385
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The American Urological Association symptom score in the evaluation of men with lower urinary tract symptoms: at 2 years of followup, does it work?
    Kaplan SA; Olsson CA; Te AE
    J Urol; 1996 Jun; 155(6):1971-4. PubMed ID: 8618299
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Benign prostatic hyperplasia evaluation and management by urologists and primary care physicians: practice patterns from the observational BPH registry.
    Wei JT; Miner MM; Steers WD; Rosen RC; Seftel AD; Pasta DJ; Carman WJ; Roehrborn CG;
    J Urol; 2011 Sep; 186(3):971-6. PubMed ID: 21791352
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differences in initial benign prostatic hyperplasia management between primary care physicians and urologists.
    Hollingsworth JM; Hollenbeck BK; Daignault S; Kim SP; Wei JT
    J Urol; 2009 Nov; 182(5):2410-4. PubMed ID: 19765742
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Economic modeling to assess the costs of treatment with finasteride, terazosin, and transurethral resection of the prostate for men with moderate to severe symptoms of benign prostatic hyperplasia.
    Lowe FC; McDaniel RL; Chmiel JJ; Hillman AL
    Urology; 1995 Oct; 46(4):477-83. PubMed ID: 7571214
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Geographic variations in the use of medical and surgical therapies for benign prostatic hyperplasia.
    Sung JC; Curtis LH; Schulman KA; Albala DM
    J Urol; 2006 Mar; 175(3 Pt 1):1023-7. PubMed ID: 16469610
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impact of medical therapy on surgery for benign prostatic hyperplasia: a study comparing changes in a decade (1992-2002).
    Vela-Navarrete R; Gonzalez-Enguita C; Garcia-Cardoso JV; Manzarbeitia F; Sarasa-Corral JL; Granizo JJ
    BJU Int; 2005 Nov; 96(7):1045-8. PubMed ID: 16225526
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Latest trends and recommendations on epidemiology, diagnosis, and treatment of benign prostatic hyperplasia (BPH)].
    Gabuev A; Oelke M
    Aktuelle Urol; 2011 May; 42(3):167-78. PubMed ID: 21604233
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of benign prostatic hyperplasia: surgery, medical therapy, or watchful waiting.
    Sall M; Bruskewitz RC
    Compr Ther; 1996 Sep; 22(9):554-8. PubMed ID: 8902346
    [No Abstract]   [Full Text] [Related]  

  • 11. Prognostic role of prostate-specific antigen and prostate volume for the risk of invasive therapy in patients with benign prostatic hyperplasia initially managed with alpha1-blockers and watchful waiting.
    Mochtar CA; Kiemeney LA; Laguna MP; van Riemsdijk MM; Barnett GS; Debruyne FM; de la Rosette JJ
    Urology; 2005 Feb; 65(2):300-5. PubMed ID: 15708042
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of 5-alpha-reductase inhibitors on the number of prostatectomies for benign prostatic hyperplasia.
    Agha AH; Roy JB; Culkin DJ; Lyon K
    Adv Ther; 1995; 12(6):361-6. PubMed ID: 10163332
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incontinence related to management of benign prostatic hypertrophy.
    Han E; Black LK; Lavelle JP
    Am J Geriatr Pharmacother; 2007 Dec; 5(4):324-34. PubMed ID: 18179990
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Benign prostatic hyperplasia: a review.
    Ramsey EW
    Can J Urol; 2000 Dec; 7(6):1135-43. PubMed ID: 11151094
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of percent free prostate-specific antigen levels in men with benign prostatic hyperplasia treated with finasteride, terazosin, or watchful waiting.
    Keetch DW; Andriole GL; Ratliff TL; Catalona WJ
    Urology; 1997 Dec; 50(6):901-5. PubMed ID: 9426721
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A population based study of incidence and treatment of benign prostatic hyperplasia among residents of Olmsted County, Minnesota: 1987 to 1997.
    Sarma AV; Jacobson DJ; McGree ME; Roberts RO; Lieber MM; Jacobsen SJ
    J Urol; 2005 Jun; 173(6):2048-53. PubMed ID: 15879823
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Benign prostatic hyperplasia. The Saudi perspective in the year 2000.
    Mosli HA; Atwa MA; Mahassini SH
    Saudi Med J; 2000 Oct; 21(10):915-20. PubMed ID: 11369951
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Benign prostatic hyperplasia: diagnosis and treatment. Agency for Health Care Policy and Research.
    McConnell JD; Barry MJ; Bruskewitz RC
    Clin Pract Guidel Quick Ref Guide Clin; 1994 Feb; (8):1-17. PubMed ID: 7507389
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Benign prostatic hyperplasia in older men.
    Gerber GS
    Clin Geriatr Med; 1998 May; 14(2):317-31. PubMed ID: 9536108
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current treatment of BPH.
    Roylance P; Gibelin B; Espié J
    Biomed Pharmacother; 1995; 49(7-8):332-8. PubMed ID: 8562858
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.